Live Analyst Rating Changes 19795 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jeff Johnson
BAIRD

Jeff Johnson

Robert W. Baird
Wall Street Analyst
★★★☆☆
#1464
on 13Foresight · ranked by our own returns
57%
Success Rate
+5.6%
Average Return
13 of 23 calls profitable · -1.8% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 57% of Jeff Johnson's ratings turned a profit when each position was held for 1 year — averaging +5.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

33 Buy 15 Hold 0 Sell
Jeff's Stock Coverage 17 ratings · 2026-08-07
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
NVST
Envista Holdings
 Aug 06, 2026 BUY Buy
+11.9% avg upside
19 analysts
$34.00
24.24% Upside
 +2.8% ·
ZBH
Zimmer Biomet Holdings
 Aug 06, 2026 HOLD Buy
+16.2% avg upside
38 analysts
$104.00
6.96% Upside
 -0.7% ·
PODD
Insulet
 Aug 06, 2026 BUY Strong Buy
+61.2% avg upside
32 analysts
$175.00
25.57% Upside
 +0.0% ·
HSIC
Henry Schein
 Aug 05, 2026 BUY Buy
+2.1% avg upside
25 analysts
$109.00
23.55% Upside
 +0.0% ·
DXCM
Dexcom
 Jul 31, 2026 BUY Strong Buy
+26.2% avg upside
32 analysts
$105.00
26.53% Upside
 +1.6% ·
INMD
InMode
 Jul 14, 2026 HOLD Buy
+28.4% avg upside
9 analysts
$17.00
12.40% Upside
 +2.6% ·
COO
Cooper Co
 Jun 05, 2026 BUY Buy
+80.7% avg upside
21 analysts
$85.00
15.95% Upside
 +10.0% ·
ENOV
Enovis
 May 08, 2026 BUY Strong Buy
+151.8% avg upside
39 analysts
$37.00
40.62% Upside
 +7.5% ·
CH:ALC
Alcon
 May 07, 2026 BUY Buy
+25.4% avg upside
35 analysts
$72.56
28.52% Upside
 +14.1% ·
SYK
Stryker
 May 01, 2026 BUY Strong Buy
+9.2% avg upside
37 analysts
$385.00
14.17% Upside
 +14.3% ·
XRAY
DENTSPLY SIRONA
 Feb 27, 2026 HOLD Buy
+117.2% avg upside
25 analysts
$14.00
6.22% Upside
 -8.9% ·
BBNX
Beta Bionics, Inc.
 Feb 18, 2026 HOLD Strong Buy
+52.4% avg upside
13 analysts
$14.00
0.69% Downside
 -5.7% ·
ALGN
Align Tech
 Feb 05, 2026 BUY Strong Buy
+74.0% avg upside
21 analysts
$218.00
28.93% Upside
 -1.1% ·
TNDM
Tandem Diabetes Care
 Dec 16, 2025 BUY Buy
+72.2% avg upside
29 analysts
$30.00
59.69% Upside
 -13.9% ·
BSX
Boston Scientific
 Dec 21, 2023 BUY Strong Buy
+38.2% avg upside
38 analysts
 — +59.8% ·
ENVX
Enovix
 May 05, 2023 BUY Strong Buy
+445.2% avg upside
19 analysts
$67.00
1472.74% Upside
 -20.2% ·
LNTH
Lantheus
 Apr 11, 2016 HOLD Buy
-18.5% avg upside
21 analysts
 — · ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jeff Johnson — Frequently Asked Questions
How accurate are Jeff Johnson's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Jeff's ratings were profitable over a one-year hold, with an average return of +5.7% per rating, or -2.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jeff ranked on 13Foresight?
Jeff Johnson is currently ranked #1464 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jeff cover?
Jeff most recently has ratings on NVST, ZBH, PODD, HSIC, DXCM, INMD, COO, ENOV, CH:ALC, SYK, XRAY, BBNX and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.